In our

series 80, 12, 14, 25 and 1 patients were respectively infected by HCV genotype 1,2,3,4 and 5. The mean viral load was 5.5.± 0.7 Log UI/mL. Thirty eight patients were IL28B (rs1 2979860) CC and 80 were either CT or TT. Mir-122 expression was assessed in check details a total of 127 percutaneous liver biopsies and 83 serums, by RT-q-PCR. Results We found a significant decrease of hepatic mir-122 expression in F3 and F4 as compared to F1 and F2 patients within all HCV patients (p=0.01) and within the 80 HCV genotype 1 infected patients (p=0.04). Whereas a trend was found between hepatic mir-122 expression in mild (F1) fibrosis vs F2-4 within all HCV genotypes (p=0.06) a significant decreased hepatic mir-122 was observed in mild (F1) fibrosis when compared to F2-F4 patients infected by HCV genotype 1 (p=0.01). We found no association between hepatic and serum expression of mir-122 (p=0.21). We found no relationship between the expression

of serum mir-122 and the different stages of fibrosis. Among patients with F1 and F2, 29.3% and 70.7% were respectively CC and CT+TT. Among patients with F3 and F4, 36.5% were CC and 63.4% were CT+TT. A 2.5 fold increase in the mean expression of serum mir-122 was found in male compared to women (p=0.05 in univariate and p=0.009 in multivariate analysis). Conclusions The major novelty of our work http://www.selleckchem.com/products/PD-0332991.html consists in the description of decrease of hepatic mir-122 expression in patients with advances stages

of fibrosis. More specifically in patients with genotype 1, hepatic mir-122 expression is increased in mild (F1) fibrosis as compared to more advanced fibrosis, in HCV genotype 1. Mir-122 might play a role in fibrogenesis during chronic hepatitis C. Disclosures: Olivier Lada – Grant/Research Support: Gilead Dominique Valla – Board Membership: Sequana Medical; Independent Contractor: IRIS; Speaking and Teaching: Mayoly Spindler, MSD, Janssen Pharmaceuticals Patrick Marcellin – Consulting: Roche, Gilead, BMS, Vertex, Novartis, Janssen-Tibotec, MSD, Boehringer, 上海皓元医药股份有限公司 Pfizer, Abbott, Alios BioPharma; Grant/Research Support: Roche, Gilead, BMS, Novartis, Janssen-Tibotec, MSD, Alios BioPharma; Speaking and Teaching: Roche, Gilead, BMS, Vertex, Novartis, Janssen-Tibotec, MSD, Abbott Tarik Asselah – Consulting: BMS, Boehringer-Ingelheim, Roche, Merck-Schering Plough, Gilead, Janssen The following people have nothing to disclose: Emilie Estrabaud, Kevin Appourchaux, Philippe Broet, Martine Lapalus, Simon De Muynck, Michelle Martinot-Peignoux, Ivan Bieche, Pierre Bedossa, Michel Vidaud Background and aims: Liver fibrosis represents a complication of many chronic liver diseases and is linked with high morbidity and mortality. However, the molecular processes driving hepatic fibrogenesis are only incompletely understood.